Drugs / Gallium-68-tilmanocept
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05446324 | Feb 2023 → Jul 2024 | endometrial cancer | UMC Utrecht | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gallium-68-tilmanocept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05446324 ↗ |
| Modality | Diagnostic / imaging agent | “the radiotracer Gallium-68-tilmanocept (68Ga-tilmanocept) PET/CT” NCT05446324 ↗ |